Date	Firm	Action	Rating
Apr 4, 2025	Maxim Group	DOWNGRADE	Buy → Hold
Jul 24, 2023	Maxim Group	UPGRADE	Hold → Buy
Aug 8, 2022	Maxim Group	DOWNGRADE	Buy → Hold
Aug 8, 2022	Canaccord Genuity	DOWNGRADE	Buy → Hold
May 18, 2022	Raymond James	DOWNGRADE	Outperform → Market Perform

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-0.38	$-0.38 — $-0.38	39% YoY	1
Next Q	$-0.39	$-0.39 — $-0.39	38% YoY	1
Current FY	$-1.56 ▼ -83.5%	$-1.56 — $-1.56	35% YoY	1
Next FY	$-0.90 ▼ -63.6%	$-0.90 — $-0.90	42% YoY	1

Latest Reports

BULLISH 6-K 7/10

Galmed Pharmaceuticals (GLMD) entered into a definitive agreement to acquire Colospan Ltd., a medical device company wit

Jun 8, 2026

NEUTRAL 6-K 4/10

Galmed Pharmaceuticals announced preclinical results from a collaboration with Tissue Dynamics, identifying a previously

Jun 2, 2026

Reddit Sentiment

78°

Bullish

Bearish Neutral Bullish

5 mentions 5 bullish 0 bearish

∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

6 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 5.8/10.

BULLISH 6-K 7/10

Galmed Pharmaceuticals (GLMD) entered into a definitive agreement to acquire Colospan Ltd., a medica

Jun 8, 2026

NEUTRAL 6-K 4/10

Galmed Pharmaceuticals announced preclinical results from a collaboration with Tissue Dynamics, iden

Jun 2, 2026

BULLISH 6-K 7/10

Galmed announced positive Phase 1 PK results for its oral Aramchol Meglumine (AM) formulation, showi

May 14, 2026

NEUTRAL 6-K 3/10

Galmed Pharmaceuticals announced a collaboration with Tissue Dynamics to develop a human cardiac fib

May 6, 2026

BULLISH 6-K 7/10

Galmed Pharmaceuticals announced a research collaboration with Tel Aviv University to evaluate its S

Apr 14, 2026

BULLISH 6-K 7/10

Galmed announced the development of a brain-penetrant formulation of its SCD1 inhibitor, Aramchol, i

Apr 9, 2026

∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Apr 2025): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-03-31	$-0.38	$-0.38	$-0.38	38.7%	—	—	$0.0B	—	1
Next Q 2026-06-30	$-0.39	$-0.39	$-0.39	38.1%	—	—	$0.0B	—	1
Current FY 2026-12-31	$-1.56	$-1.56	$-1.56	34.7%	-83.5%	0↑ 1↓	$0.0B	0.0%	1
Next FY 2027-12-31	$-0.90	$-0.90	$-0.90	42.3%	-63.6%	0↑ 1↓	$0.0B	0.0%	1

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.380
7d ago	$0.000	-0.380
30d ago	$0.000	-0.380
60d ago	$0.000	-0.380
90d ago	$0.000	-0.380

13 analyst firms have rated this stock: 2 upgrades, 7 downgrades, 11 initiations.

Historical Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Apr 4, 2025	Maxim Group	DOWNGRADE	Buy	Hold
Jul 24, 2023	Maxim Group	UPGRADE	Hold	Buy
Aug 8, 2022	Maxim Group	DOWNGRADE	Buy	Hold
Aug 8, 2022	Canaccord Genuity	DOWNGRADE	Buy	Hold
May 18, 2022	Raymond James	DOWNGRADE	Outperform	Market Perform
May 3, 2022	HC Wainwright & Co.	DOWNGRADE	Buy	Neutral
May 3, 2022	Raymond James	MAINTAIN	—	Outperform
May 17, 2021	Canaccord Genuity	MAINTAIN	—	Buy
Mar 19, 2021	HC Wainwright & Co.	MAINTAIN	—	Buy
Jan 8, 2021	Raymond James	MAINTAIN	—	Outperform
Nov 25, 2020	Canaccord Genuity	MAINTAIN	—	Buy
May 22, 2020	B. Riley Securities	DOWNGRADE	Buy	Neutral
May 15, 2020	Raymond James	MAINTAIN	—	Outperform
Mar 13, 2020	Stifel	MAINTAIN	—	Buy
Mar 13, 2020	B. Riley Securities	MAINTAIN	—	Buy
Feb 4, 2020	Craig-Hallum	INITIATE	—	Buy
Jul 22, 2019	Laidlaw & Co.	INITIATE	—	Buy
Dec 12, 2018	B. Riley Securities	INITIATE	—	Buy
Jul 20, 2018	Raymond James	INITIATE	—	Outperform
Jul 13, 2018	Stifel	INITIATE	—	Buy
Jul 11, 2018	Cantor Fitzgerald	INITIATE	—	Overweight
Jun 13, 2018	Maxim Group	MAINTAIN	Buy	Buy
Mar 15, 2018	Maxim Group	UPGRADE	Hold	Buy
Feb 14, 2018	Maxim Group	DOWNGRADE	Buy	Hold
Nov 15, 2017	Roth Capital	INITIATE	—	Buy
Oct 6, 2017	Seaport Global	INITIATE	—	Buy
Jun 23, 2015	HC Wainwright & Co.	INITIATE	—	Buy
May 6, 2015	SunTrust Robinson Humphrey	INITIATE	—	Buy
Apr 15, 2015	Roth Capital	INITIATE	—	Buy
May 9, 2014	MLV & Co.	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Hold	Sell	Strong Sell	Buy %
Jun 1, 2026	3	1	2	0%
May 1, 2026	3	1	2	0%
Apr 1, 2026	3	1	2	0%
Mar 1, 2026	3	1	2	0%
Feb 1, 2026	3	1	2	0%
Jan 1, 2026	3	1	2	0%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

78°

Bullish

Bearish Neutral Bullish

5 mentions 5 bullish 0 bearish 4 time periods

Reddit Sentiment History

Date	Mentions	Sentiment	Bullish	Threads
May 29, 2026	2	67° Warm	2	2
May 29, 2026	1	60° Warm	1	1
Apr 9, 2026	1	60° Warm	1	1
Apr 9, 2026	1	60° Warm	1	1

Recent Reddit Threads

r/pennystocks Bullish 11d 11h ago

$GLMD or $PRFX — which setup are you watching?

▲ 1 💬 1 ⚡ 0.2

r/pennystocks Bullish 11d 11h ago

$GLMD Stacking Back-to-Back Greens While $PRFX Had the Big AH Rip- both Isreal Bio companies 👀

▲ 1 💬 1 ⚡ 0.2

r/pennystocks Bullish 2mo ago

$GLMD +20% -- brain-penetrating drug breakthrough sends biotech surging premarket

▲ 1 💬 0 ⚡ 0.5

Jun 1, 2026

earnings_calendar

GLMD Q1 2026 Earnings Scheduled — 2026-06-01

May 20, 2026

earnings_calendar

GLMD Q1 2026 Earnings Scheduled — 2026-05-20

Apr 10, 2026

short_interest

FTD: GLMD — 1,174,685 shares ($0.9M) failed to deliver

Settlement: 20260410, Price: $0.79, FTD Value: $928,001.15, GALMED PHARMACEUTICALS LTD SHS

Apr 9, 2026

short_volume

Short Volume: GLMD — 57.3% short (28.6M / 49.9M)

Short: 28,576,761 | Exempt: 304,349 | TRF Vol: 49,900,056 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)

Mar 31, 2026

earnings_calendar

GLMD Q4 2025 Earnings After Market Close — 2026-03-31